Zhen Hong, Xintong Wu, Suiqiang Zhu, Shuizhen Zhou, Xiong Han, Meiping Ding, Weiping Liao, Hesheng Zhang, Raowei Yan, Yanchun Deng, Guoxing Zhu, Xin Wang, Kai Zhang, Xiaoshan Wang, Peimin Yu, Dong Zhou, Xuefeng Wang, Xuewu Liu, Xiaorong Liu, Jian Zhou, Bo Xiao, Yuping Wang, Liemin Zhou, Weihong Lin, Tiancheng Wang, Xiangqing Wang, Shuli Liang
Journal: Seizure 2025;127():105-114
PMID: 40121855
PURPOSE
To provide consensus-based recommendations for the use of sodium channel blockers (SCBs) in the management of focal epilepsy.
METHODS
A three-round modified Delphi procedure was conducted among a Delphi panel of 24 Chinese experts to build a consensus. A steering committee developed 9 statements related to SCBs for the treatment of focal epilepsy, and these statements were evaluated and voted upon by the expert panel.
RESULTS
The expert panel achieved consensus on nine statements regarding the treatment recommendations for oxcarbazepine, lamotrigine, lacosamide, eslicarbazepine, topiramate, zonisamide and cenobamate in focal epilepsy patients and treatment adjustments for SCBs.
CONCLUSION
This is a Chinese expert consensus on the use of SCBs in focal epilepsy developed using the modified Delphi method. These recommendations can help clinicians in their practice and guide future research.
Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.